Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biocartis, Covance Sign Commercialization Agreement for Idylla

Biocartis, Covance Sign Commercialization Agreement for Idylla

Apr 23, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis has announced that it has signed a commercialization agreement with Covance, the clinical research organization owned by Laboratory Corporation of America, to offer its Idylla platform and oncology assay menu to Covance's global customer base.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. Inflammatix Receives $1.1M DARPA Award to Develop Predictive COVID-19 Diagnostic

  2. Israeli Startup LessTests Uses Single-Step Pooling Software to Multiply COVID-19 Testing Capacity

    Premium

  3. FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

  4. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  5. Swift Biosciences, BillionToOne Partner to Commercialize COVID-19 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.